Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Pacific Edge named Top Bioscience Company in 2014

Pacific Edge named Top Bioscience Company in 2014


Pacific Edge has been named NZBIO’s top bioscience company for 2014. Pacific Edge was specifically recognised for building the profile and credibility of biotechnology and biotechnology companies in New Zealand.

The announcement of the industry accolade this week is further recognition for the Dunedin based cancer diagnostic company and comes a few months after taking the Supreme Award at the NZ Innovation Council Awards.

Pacific Edge Chief Executive Office David Darling says the Company is delighted to receive the recognition for the advances being made to the clinical capability for the detection and management of cancers. The company’s Urine Sampling System is becoming a core element of the advances in clinical utility, which can be used by the patient in-home to take a sample.

“It is rare in the biotechnology sector to have a company with the capability and resources to go from discovery science all the way through clinical trials and product development to finally making a commercial product as Pacific Edge has done with Cxbladder – our molecular diagnostic test for bladder cancer.”

Cxbladder is a non-invasive test with the Company’s easy to use Urine Sampling System becoming a core element of the advances in clinical utility, which allows patients can use at home. The sample is analysed in one of Pacific Edge’s laboratories for the tell-tale molecular markers that will provide the urologist with information on the probability of the patient having bladder cancer, or not.

Cxbladder is now available commercially in the United States through the company’s own CLIA and CAP regulated laboratory in Hershey, Pennsylvania. In the later part of 2013 the company signed three large, preferred national provider networks. These provider networks provide patients access to healthcare services and technology by contracting with providers and payers on a national basis. These three agreements signed with FedMed, ACPN and Stratose give millions of Americans access to Cxbladder and its positive benefits as a quick, cost effective, non-invasive and highly accurate cancer detection test that is particularly appealing to US healthcare professionals, patients, and insurers.

The custom built, commercial laboratory for Pacific Edge’s US subsidiary PEDUSA was completed in September 2012 to process Cxbladder samples, was certified in 2013 by CLIA and more recently by CAP, to enable the laboratory to offer Cxbladder as a Laboratory Developed Test (LDT) to clinicians and physicians.

Ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Media: Julian Wilcox Leaves Māori TV

Māori Television has confirmed the resignation of Head of News and Production Julian Wilcox. Mr Maxwell acknowledged Mr Wilcox’s significant contribution to Māori Television since joining the organisation in 2004. More>>

ALSO:

Genetics: New Heat Tolerant Cow Developed

Hamilton, New Zealand-based Dairy Solutionz Ltd has led an expert genetics team to develop a new dairy cow breed conditioned to thrive in lower elevation tropical climates and achieve high milk production under heat stress. More>>

Fractals: Thousands More Business Cards Needed To Build Giant Sponge

New Zealand is taking part in a global event this weekend to build a Menger Sponge using 15 million business cards but local organisers say they are thousands of business cards short. More>>

Scoop Business: NZ Net Migration Rises To Annual Record In September

New Zealand’s annual net migration rose to a record in September, beating government forecasts, as the inflow was spurred by student arrivals from India and Kiwis returning home from Australia. More>>

ALSO:

Scoop Business: Fletcher To Close Its Christchurch Insulation Plant, Cut 29 Jobs

Fletcher Building, New Zealand’s largest listed company, will close its Christchurch insulation factory, as it consolidates its Tasman Insulations operations in a “highly competitive market”. More>>

ALSO:

Scoop Business: Novartis Adds Nine New Treatments Under Pharmac Deal

Novartis New Zealand, the local unit of the global pharmaceuticals firm, has added nine new treatments in a far-ranging agreement with government drug buying agency, Pharmac. More>>

ALSO:

Crown Accounts: English Wary On Tax Take, Could Threaten Surplus

Finance Minister Bill English is warning the tax take may come in below forecast in the current financial year, as figures released today confirm it was short by nearly $1 billion in the year to June 30 and English warned of the potential impact of slumping receipts from agricultural exports. More>>

ALSO:

Get More From Scoop

 
 
Standards New Zealand

Standards New Zealand

Mosh Social Media
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news